June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Effect of botulinum toxin type A treatment on eyelid pressure in patients with blepharospasm
Author Affiliations & Notes
  • Koji Namiguchi
    Ophthalmology, Ehime University, Graduate School of Medicine, Toon-city, Ehime, Japan
  • Atsushi Shiraishi
    Ophthalmology, Ehime University, Graduate School of Medicine, Toon-city, Ehime, Japan
  • Footnotes
    Commercial Relationships   Koji Namiguchi, None; Atsushi Shiraishi, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3833. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Koji Namiguchi, Atsushi Shiraishi; Effect of botulinum toxin type A treatment on eyelid pressure in patients with blepharospasm. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3833.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine the effect of botulinum toxin type A treatment on the eyelid pressure in the patients with blepharospasm.

Methods : Twenty normal volunteers (10 males, 10 females average age 59.7 ±11.3 years old), and 33 patients (12 men, 21 females average age 61.1 ± 14.7 years old) who were diagnosed with blepharospasm at the Ehime University Hospital from March 2013 to August 2015 were studied. The upper and lower eyelid pressures were measured using the eyelid pressure measuring device (DigiTects single point tactile sensor, Pressure Profile System) for normal subjects (N group), and the eyelid pressures were measured before and after 2 to 4 weeks of botulinum toxin type A treatment for the patients (B group).

Results : The mean eyelid pressure of N group was 31.0 ± 6.8 mmHg for the upper eyelid, and 29.9 ± 6.5 mmHg for the lower eyelid. The mean eyelid pressure before treatment was 35.3 ± 7.0 mmHg for the upper eyelid, and 37.8 ± 6.6 mmHg for the lower eyelid in B group. The eyelid pressure of N group blepharospasm was significantly higher than those of N group in the upper (p <0.001) and the lower (p <0.001) eyelid. The mean eyelid pressure after treatment was 29.9 ± 7.5 mmHg for the upper eyelid and 32.8 ± 7.0 mmHg for the lower eyelid in B group. The eyelid pressure were significantly decreased after botulinum toxin type A treatment in the upper (p <0.001) and the lower (p <0.001) eyelid.

Conclusions : <span lang="EN" style="color:rgb(34, 34, 34); font-family:arial,sans-serif; font-size:10.5pt; margin:0px">The eyelid pressure of the patients with blepharospasm was significantly higher than those of normal volunteers, ande decreased after botulinum toxin type A treatment. The results suggest that higher eyelid pressure may cause of the symptoms blepharospasm<span style="margin:0px"> </span>and decreased eyelid pressure by botulinum toxin type A treatment may contribute the alleviation of the symptoms. The eyelid measurement system can be useful diagnostic tools for the severity or treatment effect of blepharospasm.</span>

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×